Organon (OGN) Change in Account Payables (2020 - 2026)
Organon (OGN) posted quarterly Change in Account Payables of $74.0 million for Q2 2026, up 85.0% year-over-year from $40.0 million in Q2 2025, and up 131.25% on a QoQ basis from $32.0 million in Q1 2026.
Organon (OGN) Change in Account Payables (2020 - 2026) Analysis & Trends
Organon has reported Change in Account Payables for 7 years, with the latest figure at $74.0 million in Q2 2026.
- Change in Account Payables for Q2 2026 came in at $74.0 million, up 85.0% year-over-year; the trailing twelve-month figure through Jun 2026 was -$2.0 million (up 99.05% YoY), and the FY2025 annual result was -$217.0 million, down 38.22% from the prior year.
- Change in Account Payables grew to $74.0 million in Q2 2026, from $32.0 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $293.0 million in Q2 2024 and troughed at -$349.0 million in Q1 2024.
- A 5-year average of -$19.0 million and a median of $22.0 million in 2025 frame the typical range for Change in Account Payables.
- The widest annual swing landed in 2023, when Change in Account Payables soared 168.6%; it then plunged 306.9% in 2025.
- A 5-year view of Change in Account Payables shows it stood at $86.0 million in 2022, then surged by 168.6% to $231.0 million in 2023, then tumbled by 74.89% to $58.0 million in 2024, then sank by 306.9% to -$120.0 million in 2025, then jumped by 161.67% to $74.0 million in 2026.
- Per Business Quant data, the three most recent Change in Account Payables figures were $74.0 million in Q2 2026, $32.0 million in Q1 2026, and -$120.0 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -70.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 18.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn | 74.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 74.00 Mn |
| Jun 30, 2026 | 74.00 Mn |
| Mar 31, 2026 | 32.00 Mn |
| Mar 31, 2026 | 32.00 Mn |
| Dec 31, 2025 | -120.00 Mn |
| Dec 31, 2025 | -120.00 Mn |
| Sep 30, 2025 | 12.00 Mn |
| Sep 30, 2025 | 12.00 Mn |
| Jun 30, 2025 | 40.00 Mn |
| Jun 30, 2025 | 40.00 Mn |
| Mar 31, 2025 | -149.00 Mn |
| Mar 31, 2025 | -149.00 Mn |
| Dec 31, 2024 | 58.00 Mn |
| Dec 31, 2024 | 58.00 Mn |
| Sep 30, 2024 | -159.00 Mn |
| Sep 30, 2024 | -159.00 Mn |
| Jun 30, 2024 | 293.00 Mn |
| Jun 30, 2024 | 293.00 Mn |
| Mar 31, 2024 | -349.00 Mn |
| Mar 31, 2024 | -349.00 Mn |